Commonwealth Fund March 12, 2020
Jesse C. Baumgartner, Lovisa Gustafsson

Toplines

Comparative effectiveness research can be a powerful tool to bring down the cost of drugs

An increased role for comparative effectiveness research would help U.S. payers lower drug costs and prioritize the most effective medications

Most of us are aware that the United States spends far more on prescription drugs than other high-income countries do. Probably less well known is that Americans also use more drugs and treatments that provide only marginal clinical benefit. So why do people around the world not only spend less, but receive medicines that are more effective?

In part, it’s because most other countries rely on comparative effectiveness research (CER) to...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: ACA (Affordable Care Act), CMS, Congress / White House, Govt Agencies, Insurance, Patient / Consumer, Payer, Provider, Public Exchange
Related Articles:
Payer executives expect limited change in ACA subsidies
Commercial, individual markets growing increasingly concentrated: 7 numbers to know
GAO finds private insurance market became increasingly concentrated last decade
Section 1557 Rule Mandates Identification And Mitigation Of Discriminatory Clinical Algorithms
Employer Plans Beware: Alternative Funding Programs May Be Riskier Than They Appear

Share This Article